Kevin Cooper

Trials

Studies that name Kevin Cooper as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:44 UTC. Open this list on ClinicalTrials.gov

• Ph4
  NCT05270733 · Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

  University Hospitals Cleveland Medical Center · recruiting · Psoriasis · principal investigator
• N/A
  NCT05106192 · Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

  Case Comprehensive Cancer Center · withdrawn · Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma · principal investigator
• Ph1/Ph2
  NCT04489628 · Tele-health Enabled Clinical Trial for COVID-19

  University Hospitals Cleveland Medical Center · withdrawn · SARS-CoV Infection · principal investigator
• Ph2
  NCT03442088 · Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

  University Hospitals Cleveland Medical Center · completed · Plaque Psoriasis · study chair
• N/A
  NCT02457000 · Sleep, Circadian Rhythm & Skin Health

  University Hospitals Cleveland Medical Center · completed · Healthy, Psoriasis, Eczema · principal investigator
• Ph1/Ph2
  NCT00961220 · O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

  National Cancer Institute (NCI) · completed · Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7 · principal investigator
• Ph1
  NCT00103246 · Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

  Case Comprehensive Cancer Center · completed · Lymphoma, Non-melanomatous Skin Cancer, Precancerous Condition · principal investigator
• Ph1
  NCT00003613 · O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

  National Cancer Institute (NCI) · terminated · Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 07:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Administrative Core
  P50AR070590 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2017 to 2021 · $331,382 awarded in 2021
  Same name and institution; not confirmed by an ID
• Case Investigative & Translational Dermatology Training Program
  T32AR007569 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2003 to 2019 · $253,814 awarded in 2019
  Same name and institution; not confirmed by an ID
• Core D: Animal Experimentation & Wound Healing
  P30AR039750 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 1997 to 2015 · $167,746 awarded in 2015
  Same name and institution; not confirmed by an ID
• Psoriatic Regulatory T cell Dysfunction
  R01AR051498 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2004 to 2014 · $391,363 awarded in 2014
  Same name and institution; not confirmed by an ID
• PPAR-gamma Signaling in Normal Pilosebaceous Units and in Scarring Alopecia
  R01AR056245 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2013 · $139,500 awarded in 2013
  Same name and institution; not confirmed by an ID
• S100 A8/A9 and Macrophages in Psoriasis
  P50AR055508 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2007 to 2011 · $215,802 awarded in 2011
  Same name and institution; not confirmed by an ID
• Multicenter Trial of O6BG and Topical BCNU for CTCL
  R21CA115057 · NCI · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2006 to 2007 · $286,763 awarded in 2007
  Grant number is on one of their registry trials
• Normal and UV-Induced cutaneous antigen presenting cells
  R01AI041766 · NIAID · CASE WESTERN RESERVE UNIVERSITY · fiscal years 1997 to 2007 · $253,876 awarded in 2007
  Same name and institution; not confirmed by an ID
• O6-BENZYLGUANINE AND BCNU IN CUTANEOUS T-CELL LYMPHOMA
  M01RR000080 · NCRR · CASE WESTERN RESERVE UNIVERSITY · fiscal years 1998 to 2006 · $4,399 awarded in 2006
  Same name and institution; not confirmed by an ID
• UV-induced Immunosuppression to chemical toxicants
  R01ES012043 · NIEHS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 2002 to 2006 · $336,161 awarded in 2006
  Same name and institution; not confirmed by an ID
• Experimental and Clinical Contact Dermatitis Meetings
  R13AR049012 · NIAMS · UNIVERSITY HOSPITALS OF CLEVELAND · fiscal years 2002 · $15,000 awarded in 2002
  Same name and institution; not confirmed by an ID
• INTERACTION BETWEEN PSORIATIC KERATINOCYTES AND T CELLS
  R01AR041707 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 1996 to 2001 · $265,392 awarded in 2001
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Cancer Genomics and Epigenomics
  P30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Zhenghe Wang · fiscal years 2009 to 2026
  Named on NCT00961220, NCT00103246
• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
  U01CA062502 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI AFSHIN DOWLATI · fiscal years 2009 to 2013
  Named on NCT00961220, NCT00003613